Please assess the completion status of the following clinical trial:

Trial Title: STOP Heart Disease in Breast Cancer Survivors Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients with newly diagnosed stage 1-3 breast cancer~* Histologically confirmed HER2, ER, and PR status~* Recommended to undergo trastuzumab treatment, with or without anthracycline. Patients will be eligible for up to 3 weeks after starting treatment.~* Age minimum 18 years~* Able and willing to read, understand, and sign an informed consent form (ICF) and medical release form~* Willing and able to comply with trial protocol and follow-up~* ECOG performance status 0-1 (Karnofsky ≥ 70%)~Exclusion Criteria:~* Prior use of statin medication within the past year~* Not using statin medication but is eligible for statin therapy based on the 2013 ACC/AHA guidelines (LDL cholesterol \>190, or LDL \<190 and ASCVD risk \>7.5%; http://tools.acc.org/ASCVD-Risk-Estimator/) and is \> 50 years old; or is eligible for statin therapy based on the 2013 ACC/AHA guidelines and is 40-50 years old and wishes to be placed on statin therapy~* History of adverse effects, intolerance, or allergic reactions attributed to statin medication~* Current use of gemfibrozil, cyclosporine, clarithromycin, itraconazole, erythromycin, the hepatitis C protease inhibitor telaprevir, HIV protease inhibitors, colchicine, or red yeast rice~* Current use of any other investigational agent~* Pregnant or intention to get pregnant during the next 18 months. Pregnant women are excluded from this study because atorvastatin is a lipid-lowering agent with the potential for teratogenic or abortifacient effects, and MRI is contraindicated in pregnant women.~* History of diabetes, severe lung disease, renal disease (creatinine \> 1.8 mg/dL or CrCl ≤ 50 mL/min), or hepatic disease (AST and ALT \> 3 times upper normal limits)~* Abnormal baseline echocardiogram or cardiac MRI (detection of congenital heart disease; ischemic heart disease; moderate or severe valvular heart disease; cardiomyopathy; EF \< 55%)~* Previously known or diagnosed heart disease (e.g. congenital; valvular; coronary artery disease; history of myocardial infarction or acute coronary syndrome; cardiomyopathy, including infiltrative, hypertensive, hypertrophic, dilated, constrictive pericarditis, or other cardiomyopathy)~* Left ventricular dysfunction (EF \< 55%)~* Prior non-cardiac illness with an estimated life expectancy \< 4 years~* Known active infection with HIV~* Allergy or contraindication to MRI testing, including claustrophobia, metallic parts in body the prohibiting MRI, prior gadolinium contrast reaction, or uncontrolled moderate hypertension (sitting blood pressure \>160/95 mm Hg with measurements recorded on at least 2 occasions).~* Has metallic breast expanders in place at the time of screening~* Concurrent illness which in the opinion of the investigators would compromise either the patient or the integrity of the data

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study Agent (Type: EXPERIMENTAL): One atorvastatin 20 mg oral capsule per day
- Control (Type: PLACEBO_COMPARATOR): One matching placebo daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues